On 28 April 2026, Xuanzhu Biopharmaceutical Co., Ltd. (“Xuanzhu Biopharm”) issued a reminder to its registered shareholders confirming the transition to electronic dissemination of all corporate communications.

The change, first announced on 21 November 2025, covers a broad range of documents, including directors’ reports, annual and interim results (and any summaries), meeting notices, listing documents, circulars and proxy forms.

Going forward, the Company will post identical English and Chinese versions of these materials on both its own website (www.xuanzhubio.com) and HKExnews (www.hkexnews.hk), replacing routine hard-copy mailings.

Action required: • Shareholders who have not yet provided an email address are encouraged to do so by scanning the personalised QR code on the enclosed reply form or by returning the signed form to the H-share registrar, Computershare Hong Kong Investor Services Limited. • Until a functional email address is on record, Xuanzhu Biopharm will send any “Actionable Corporate Communication” (documents requiring shareholder instructions) in printed form.

Printed-copy option: Investors preferring hard copies of all future corporate communications may request them by returning the reply form or emailing xuanzhubio.ecom@computershare.com.hk. This choice remains valid for one year from the date the instruction is received.

The notice is issued under the authority of Ms Xu Yanjun, Chairperson of Xuanzhu Biopharm’s Board.